{"id":"https://openalex.org/W4362392925","doi":"https://doi.org/10.1158/1078-0432.22442477","title":"Supplementary Figure 1 from Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept","display_name":"Supplementary Figure 1 from Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4362392925","doi":"https://doi.org/10.1158/1078-0432.22442477"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22442477","doi":"https://doi.org/10.1158/1078-0432.22442477","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22442477","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Myeloid_Biomarkers_Associated_with_Glioblastoma_Response_to_Anti-VEGF_Therapy_with_Aflibercept/22442477/1/files/39893369.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Myeloid_Biomarkers_Associated_with_Glioblastoma_Response_to_Anti-VEGF_Therapy_with_Aflibercept/22442477/1/files/39893369.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055183757","display_name":"John de Groot","orcid":"https://orcid.org/0000-0003-1454-6461","observed_orcids":["https://orcid.org/0000-0003-1454-6461"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John F. de Groot","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110010918","display_name":"Yuji Piao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yuji Piao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056267838","display_name":"Hai Thanh Tran","orcid":"https://orcid.org/0000-0003-4065-9355","observed_orcids":["https://orcid.org/0000-0003-4065-9355"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hai Tran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064627876","display_name":"Mark R. Gilbert","orcid":"https://orcid.org/0000-0003-2556-9722","observed_orcids":["https://orcid.org/0000-0003-2556-9722"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Gilbert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110048252","display_name":"Hua\u2010Kang Wu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hua-Kang Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100362051","display_name":"Jun Liu","orcid":"https://orcid.org/0000-0003-2011-3961","observed_orcids":["https://orcid.org/0000-0003-2011-3961"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111432852","display_name":"Benjamin Nebiyou Bekele","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Nebiyou Bekele","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112906124","display_name":"Tim F. Cloughesy","orcid":"https://orcid.org/0000-0002-8656-7483","observed_orcids":["https://orcid.org/0000-0002-8656-7483"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tim Cloughesy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038585908","display_name":"Minesh P. Mehta","orcid":"https://orcid.org/0000-0002-4812-5713","observed_orcids":["https://orcid.org/0000-0002-4812-5713"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Minesh Mehta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057427180","display_name":"H. Ian Robins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Ian Robins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057541817","display_name":"Andrew B. Lassman","orcid":"https://orcid.org/0000-0001-7386-9928","observed_orcids":["https://orcid.org/0000-0001-7386-9928"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew Lassman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004573264","display_name":"Lisa Marie DeAngelis","orcid":"https://orcid.org/0000-0002-6290-7818","observed_orcids":["https://orcid.org/0000-0002-6290-7818"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lisa DeAngelis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036663495","display_name":"Kevin A. Camphausen","orcid":"https://orcid.org/0000-0002-0450-4877","observed_orcids":["https://orcid.org/0000-0002-0450-4877"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Camphausen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045409088","display_name":"Alice P. Chen","orcid":"https://orcid.org/0000-0002-1426-853X","observed_orcids":["https://orcid.org/0000-0002-1426-853X","https://orcid.org/0000-0002-2919-4326"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alice Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089916424","display_name":"WKA Yung","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"WKA Yung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046264008","display_name":"Michael D. Prados","orcid":"https://orcid.org/0000-0002-9630-2075","observed_orcids":["https://orcid.org/0000-0002-9630-2075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Prados","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021656597","display_name":"Patrick Yung Wen","orcid":"https://orcid.org/0000-0002-0774-7700","observed_orcids":["https://orcid.org/0000-0002-0774-7700","https://orcid.org/0000-0003-3224-3042","https://orcid.org/0000-0002-2452-0540"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick Y. Wen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5048380048","display_name":"John Victor Heymach","orcid":"https://orcid.org/0000-0001-9068-8942","observed_orcids":["https://orcid.org/0000-0001-9068-8942"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John V. Heymach","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9717000126838684,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9717000126838684,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.01810000091791153,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9890000224113464},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.8659999966621399},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9959999918937683},{"id":"https://openalex.org/keywords/myeloid-cells","display_name":"myeloid cells","score":0.8880000114440918},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.9430000185966492},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.7900000214576721},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.5239999890327454}],"concepts":[{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.9105374217033386},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6902197003364563},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.689266562461853},{"id":"https://openalex.org/C2776194525","wikidata":"https://www.wikidata.org/wiki/Q282142","display_name":"Glioblastoma","level":2,"score":0.625796377658844},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48919013142585754},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.439298152923584},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3915386199951172},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.3652079105377197},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34088170528411865},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.13007059693336487}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22442477","doi":"https://doi.org/10.1158/1078-0432.22442477","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22442477","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Myeloid_Biomarkers_Associated_with_Glioblastoma_Response_to_Anti-VEGF_Therapy_with_Aflibercept/22442477/1/files/39893369.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22442477.v1","doi":"https://doi.org/10.1158/1078-0432.22442477.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22442477.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22442477","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Myeloid_Biomarkers_Associated_with_Glioblastoma_Response_to_Anti-VEGF_Therapy_with_Aflibercept/22442477","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22442477","doi":"https://doi.org/10.1158/1078-0432.22442477","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22442477","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Myeloid_Biomarkers_Associated_with_Glioblastoma_Response_to_Anti-VEGF_Therapy_with_Aflibercept/22442477/1/files/39893369.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9476000070571899}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362392925.pdf","grobid_xml":"https://content.openalex.org/works/W4362392925.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2337759863","https://openalex.org/W6902215259","https://openalex.org/W4363675520","https://openalex.org/W2972419685","https://openalex.org/W2161190434","https://openalex.org/W4362543495","https://openalex.org/W3121579979","https://openalex.org/W2531296115","https://openalex.org/W2588614128","https://openalex.org/W2255349088"],"abstract_inverted_index":{"Supplementary":[0],"Figure":[1],"1":[2],"from":[3],"Myeloid":[4],"Biomarkers":[5],"Associated":[6],"with":[7,13],"Glioblastoma":[8],"Response":[9],"to":[10],"Anti-VEGF":[11],"Therapy":[12],"Aflibercept":[14]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}